Avoiding the Doom Loop: Innovation Realities for Orthopedic Startups

The enforced moratorium on sales during the early days of the pandemic allowed some orthopedic companies to step back and sharpen operational or developmental projects. The largest players even accelerated their R&D spending, as we saw with Zimmer Biomet when company CEO Bryan Hanson said, “We look at ROSA and other robotics-related...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us